These 7 stocks surge over 500% in first half of FY21; do you own any?

In the first half of FY21 (H1FY21), Sensex rose nearly 30 percent

Many countries, including India, had to completely or partially shut down all economic activities after the coronavirus pandemic outbreak at the start of the year. In India, a complete lockdown was announced in late March and now we are in the Unlocking phase 5. This jolt on the economy was also reflected in the market initially but the indices started to gain later. In the first half of FY21 (H1FY21), Sensex rose nearly 30 percent. During the same period, 7 stocks from the BSE universe gave over 500 percent return. We considered stocks with a market cap of over Rs 100 crore. (Data Source: ACE Equity)

Mcleod Russel India | In the first half of FY21, the stock price rose 804 percent to Rs 18.8 (as on September 30) from Rs 2.08 (as on March 31).

Praveg Communications (India) | In the first half of FY21, the stock price rose 604 percent to Rs 63.7 (as on September 30) from Rs 9.05 (as on March 31).

Birla Tyres | In the first half of FY21, the stock price rose 592 percent to Rs 20.4 (as on September 30) from Rs 2.95 (as on March 31)

Vikas Multicorp | In the first half of FY21, the stock price rose 580 percent to Rs 7.75 (as on September 30) from Rs 1.14 (as on March 31).

Venus Remedies | In the first half of FY21, the stock price rose 516 percent to Rs 138.6 (as on September 30) from Rs 22.5 (as on March 31).

Aarti Drugs | In the first half of FY21, the stock price rose 510 percent to Rs 771.55 (as on September 30) from Rs 126.45 (as on March 31).

Tanla Solutions | In the first half of FY21, the stock price rose 502 percent to Rs 292.1 (as on September 30) from Rs 48.5 (as on March 31).

Comments

Panacea Biotech shares hit 5% upper circuit after dengue vaccine completes phase I & II study

DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes, the company has said in an exchange filing. Panacea Biotech share price hit 5 percent upper circuit on the BSE on September 24 after the company completed phases I and II study of its dengue vaccine candidate DengiAIl. "Panacea Biotec Ltd. is delighted to announce the successful completion of its Phase I/II study to evaluate the safety and immunogenicity of its vaccine, DengiAll, a single-dose liveattenuated tetravalent vaccine," the company said in an exchange filing. Live-attenuated vaccines contain weakened bacteria or viruses that trigger an immune response but do not cause disease. The company said DengiAIl induced robust neutralising antibody responses against all the four dengue virus serotypes. DengiAIl has been found to be safe and well-tolerated with no serious adverse effects, the company said. After a single-dose, more than 80 percent of the participants ...

Check Chemcon Speciality Chemicals IPO allotment status in four simple steps

Equity shares will get credited into the accounts of eligible investors by September 30 and the listing of equity shares will be on October 1, 2020. Chemcon Speciality Chemicals, the manufacturer for pharmaceutical and oilfields industries, is expected to announce the basis of allotment early next week. As per the schedule provided by the company, the finalisation of the basis of the allotment will be done by September 28 and the initiation of refunds or unblocking of funds from ASBA account will take place on September 29. Equity shares will get credited to the accounts of eligible investors by September 30 and the listing will be on October The IPO comprised a fresh issue of Rs 165 crore and an offer for sale of Rs 153 crore by promoters. The company will utilise fresh issue proceeds for expansion of manufacturing facility, working capital requirements, and general corporate purposes. Chemcon manufactures specialised chemicals, such as Hexamethyldisilazane (HMDS) and Chloromethyl Iso...

Taking Stock | Profit-booking pulls Nifty below 14,450; Sensex drops 549 points

All the sectoral indices ended in the red with IT and PSU bank indices falling 2 percent each. The market remained under pressure on January 15 on the back of profit-booking across sectors amid weak global cues. At close, the Sensex was down 549.49 points or 1.11% at 49,034.67, and Nifty was down 161.90 points or 1.11% at 14,433.70. "The market witnessed profit-booking and following global trends. Nifty continues to resist 14,600 and has taken a dip towards 14,360. If the market closes below 14,380 levels, we might see a correction till the levels of 14,180-14,200. Momentum indicators like RSI, MACD are indicating a small correction in the markets," said Ashis Biswas, Head of Research at CapitalVia Global Research. All the sectoral indices ended in the red with IT and PSU bank falling 2 percent each. Broader markets performed in line with the main indices with BSE Midcap and Smallcap indices falling 1 percent each. Tech Mahindra, GAIL, HCL Tech, Wipro and ONGC...

SD Solutions

Search This Blog